EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic . . . Different EGFR conformations in lung cancer and GBM The EGFR mutations detected in GBM and non-small cell lung cancer (NSCLC) have oncogenic transforming potential and they promote strong basal phosphorylation of the receptor in vitro
Targeting EGFR and PI3K mTOR pathways in glioblastoma . . . - PubMed In most the tumor, overexpression of EGFR is found associated with GBM and mutations in its several variants are important for promoting ongoing mitogenic signaling and tumor growth This receptor inhibits apoptosis and promotes cell survival and proliferation by activating downstream PI3K AKT mTOR pathways
Abedelnasser Abulrob - Google Scholar Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae
Constitutive activation of truncated EGF receptors in glioblastoma By immunocytochemistry and measurement of in vitro binding to caveolin scaffolding domain peptides, Abulrob et al have demonstrated association of EGFRwt with caveolin-1 or -3 via the caveolin-binding motif within the kinase domain of EGFR
Epidermal growth factor receptor (EGFR) and EGFRvIII in glioblastoma . . . Here, we discuss signaling pathways mediated by EGFR EGFRvIII, current therapeutics, and novel strategies to target EGFR EGFRvIII-amplified GBM Keywords: GBM, glioblastoma, epidermal growth factor, EGFR, EGFRvIII, tyrosine kinase inhibitor, TKI Introduction
Interactions of EGFR and caveolin-1 in human glioblastoma cells . . . Epidermal growth factor receptor (EGFR) amplification and type III mutation (EGFRvIII), associated with constitutive tyrosine kinase activation and high malignancy, are commonly observed in glioblastoma tumors The association of EGFR and EGFRvIII with caveolins was investigated in human glioblastoma cell lines, U87MG and U87MG-EGFRvIII
New Findings Alter View of EGFR Signaling in Glioblastoma Signaling pathway thought to be driving oncogenesis gets called into question The epidermal growth factor receptor (EGFR) is a key oncogene that is frequently amplified in glioblastoma, and evidence has suggested that EGFR is an important oncogenic driver in this highly invasive brain tumor
Targeting EGFR for treatment of glioblastoma: molecular basis to . . . A range of potential therapies that target EGFR or its mutant constitutively active form, ΔEGFR, including tyrosine kinase inhibitors (TKIs), monoclonal antibodies, vaccines, and RNA-based agents, are currently in development or in clinical trials for the treatment of GBM